Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs NEOG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–5 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AHCO 3 – 3 NEOG Matrix Metrics: AHCO 4 – 5 NEOG

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas NEOG carries 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin).

  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile NEOG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs NEOG
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
NEOG NASDAQ
Neogen Corp
In Vitro & In Vivo Diagnostic Substances
$10.55
-2.76% 1D
Market Cap $2.4B
TTM Revenue $884M
Forward P/E 35.2x
Beta / 30D Vol 1.35β · 41% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 30.0 Fund 47.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.4%), weak momentum, RSI 34
RSI-14: 34.0 · SMA20: $11.64 · SMA50: $12.14

6-Pillar Scorecard Institutional Category Breakdown (AHCO 3 – 3 NEOG)

Columns: Metric · AHCO · NEOG
1. Valuation Multiples AHCO
Forward P/E 7.8x 35.2x
Trailing P/E 7.8x 16.0x
PEG Ratio N/M 0.66x
EV / Revenue 0.9x 3.4x
2. Growth & Scale AHCO
Revenue Growth (YoY) +10.9% +6.5%
Earnings Growth (YoY) +6.7% -85.6%
TTM Revenue (USD) $3.44B $884M
Market Cap $989.8M $2.4B
3. Profitability & Quality NEOG
Gross Margin 18.2% 47.4%
Operating Margin 3.8% -0.8%
Net Profit Margin -11.8% -6.3%
Return on Equity (ROE) -28.4% -2.7%
4. Balance Sheet & Cash Flow NEOG
Cash Generation (TTM) $82M $50M
Cash Flow Margin 2.4% 5.6%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $602M Net Debt (0.37x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 66.9% (12th %ile) 46.0% (25th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NEOG
OpEx & R&D Intensity 14.4% of Rev ($495M) 48.2% of Rev ($426M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (4) vs NEOG (5)
Institutional Metric AHCO NEOG Criterion Row Edge
Market Capitalization
Scale
$989.8M $2.4B Larger Scale NEOG
Trailing P/E Ratio
Valuation
7.8x 16.0x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 35.2x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +6.5% Higher Growth AHCO
Operating Margin (TTM)
Profitability
3.8% -0.8% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -6.3% Higher Margin NEOG
Return on Equity (ROE)
Capital Efficiency
-28.4% -2.7% Higher ROE NEOG
52-Week Range Position
Momentum
24% ($5–$13) 58% ($5–$14) Stronger Trend NEOG
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.35β · 41% Vol Lower Realized Risk NEOG
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $884M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 47.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 0.66x PEG · 3.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $50M ($602M Net Debt (0.37x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +28.63 pp
AHCO: +16.69% · NEOG: -11.94%
3M Horizon AHCO +36.94 pp
AHCO: +27.89% · NEOG: -9.05%
6M Horizon NEOG +49.64 pp
AHCO: -31.1% · NEOG: +18.54%
1Y Horizon NEOG +110.29 pp
AHCO: -20.88% · NEOG: +89.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue NEOG Revenue AHCO Op. Margin NEOG Op. Margin Margin Leader
FY2019 $530M $410M 5.5% 16.4% NEOG
FY2020 $1.06B $420M 6.8% 16.1% NEOG
FY2021 $2.45B $470M 9.2% 15.8% NEOG
FY2022 $2.97B $530M 6.4% 11.1% NEOG
FY2023 $3.20B $820M -18.7% 4.6% NEOG
FY2024 $3.26B $920M 8.1% 6.3% AHCO
FY2025 $3.24B $890M 2.8% -118.6% AHCO
FY2026 N/A $870M N/A -2.5% NEOG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NEOG CONSOLIDATION
43d in phase · OBV NEUTRAL
Current IV 46.0%
IV Percentile 25th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
NEOG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($426M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs NEOG Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas NEOG carries 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile NEOG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with NEOG at +6.5% YoY revenue growth and -85.6% YoY earnings growth on $884M TTM revenue (47.4% gross margin, -0.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AHCO cumulative revenue shifted +511.3% while NEOG shifted +112.2%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($426M) (0 disclosures) for NEOG.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas NEOG trades at 35.2x Forward P/E, 16.0x Trailing P/E, 0.66x PEG, and 3.4x EV/Revenue (5.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus NEOG (-2.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, NEOG carries 46.0% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.35β · 41% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.